Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Revenue: 2009-2025

Historic Revenue for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $799.5 million.

  • UNITED THERAPEUTICS's Revenue rose 6.76% to $799.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 13.48%. This contributed to the annual value of $2.9 billion for FY2024, which is 23.63% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Revenue is $799.5 million, which was up 0.11% from $798.6 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Revenue high stood at $799.5 million for Q3 2025, and its period low was -$7.9 million during Q4 2024.
  • For the 3-year period, UNITED THERAPEUTICS's Revenue averaged around $623.1 million, with its median value being $677.7 million (2024).
  • Within the past 5 years, the most significant YoY rise in UNITED THERAPEUTICS's Revenue was 33.70% (2024), while the steepest drop was 101.29% (2024).
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Revenue stood at $415.2 million in 2021, then climbed by 18.38% to $491.5 million in 2022, then climbed by 25.07% to $614.7 million in 2023, then slumped by 101.29% to -$7.9 million in 2024, then climbed by 6.76% to $799.5 million in 2025.
  • Its Revenue was $799.5 million in Q3 2025, compared to $798.6 million in Q2 2025 and $794.4 million in Q1 2025.